More evidence lipid drug slows diabetic retinopathy progression
Large US trial confirms fenofibrates reduce the risk of patients with non-proliferative disease moving to visually threatening forms
Patients with non-proliferative diabetic retinopathy are less likely to see their illness worsen to proliferative and vision-threatening disease if they are taking fenofibrates, a US study says.
The researchers say the findings support the inclusion of fenofibrate in the management of diabetic retinopathy, a move backed by the TGA eight years ago when it approved the drug for use in patients with type 2 diabetes and existing disease.
The drug may have a wider role than now in treating patients with non-proliferative
